SAGE PRO

Home / Research / Piramal Pharma Limited

SAGE PRO · ORIGINAL EQUITY RESEARCH

Piramal Pharma Limited — Q2 FY27 Results Analysis

Operating recovery needs a cash test

Published · Quarter Q2 FY27 · PPLPHARMA

Research periodQ2 FY27
QualitySource verified; independent QA open
COMPANY-SPECIFIC GRAPHICAL SUMMARY

What the reported figures reveal

CHART 1

Q2 revenue comparison

Q2 FY26₹2,043.72 cr
Q2 FY27₹2,617.06 cr

S1

CHART 2

Q2 EBITDA

Q2 FY26₹224 cr
Q2 FY27₹385 cr

S2

CHART 3

Q2 EBITDA margin

Q2 FY2611%
Q2 FY2714.7%

S2

CHART 4

Q2 PAT

Q2 FY26₹-99 cr
Q2 FY27₹5 cr

S2

ORIGINAL RESEARCH INSIGHTS

Investment findings and watch points

RESEARCH INSIGHT

Operating recovery needs a cash test

Revenue and EBITDA improved while operating cash weakened on an H1 basis

Watch: Watch cash-after-investment before upgrading thesis

RESEARCH INSIGHT

Operating profit is outrunning sales

Q2 EBITDA grew about 72% on the issuer's rounded basis

Watch: Test site utilization and persistent cost structure

RESEARCH INSIGHT

Higher capacity absorption is visible

Rounded Q2 EBITDA margins improved from 11.0% to 14.7%

Watch: Compare normalized Q3 margin against Q2

RESEARCH INSIGHT

The consolidated PAT cushion is narrow

Consolidated PAT moved from a loss near 99 crore to 5 crore profit

Watch: Avoid a profit-only valuation without finance and depreciation bridges

FULL PUBLISHED RESEARCH

Earnings and management commentary analysis

1. Decision thesis and variant perception

Key takeaways

  • Stance: WATCH; capital discipline is the principal test. Piramal Pharma's Q2 FY27 consolidated revenue reached Rs 2,617.06 crore versus Rs 2,043.72 crore in Q2 FY26, a 28.05% year-on-year increase.
  • EBITDA in its 27 October release rose from roughly Rs 224 crore to Rs 385 crore, with margin moving from about 11.0% to 14.7%.
  • The operating recovery is material; the corresponding consolidated PAT was only about Rs 5 crore.

This mismatch reflects a still-heavy depreciation, financing and tax burden, and gives the investment thesis an unusual asymmetry: stronger utilization can create considerable EBITDA growth without immediately creating substantial per-share profit.

The strongest negative signal is cash quality. Original consolidated half-year cash results show operating cash flow falling to Rs 390.91 crore from Rs 889.76 crore in the previous H1, despite improvement in operating profit before changes in working capital.

Cash payments for property, plant, equipment and intangibles almost doubled to Rs 858.69 crore from Rs 433.22 crore. Thus the simple H1 operating-cash-minus-disclosed-capital-purchases measure reversed from plus Rs 456.54 crore to minus Rs 467.78 crore.

This is not equivalent to audited free cash flow to equity, but it is a decisive warning against capitalizing EBITDA improvement as immediate distributable cash.

Falsifiable investment question: can growth translate into post-investment cash without continued expansion of net debt? The positive condition is sustained consolidated margin alongside working-capital normalization, fewer one-off integration costs, reliable compliance and a visible reduction in capital investment relative to internally generated cash.

The negative condition is rising sales with persistent negative operating cash after asset spending, or regulatory and site-level costs that prevent operating leverage from reaching owners. This source-verified analysis does not equate management's upgraded 19-20% FY27 revenue-growth outlook to achieved results.

2. Business economics and competitive position

Key takeaways

  • Piramal Pharma combines three economically different engines.
  • The CDMO network earns from development and manufacturing mandates whose revenue timing depends on customer programs, regulatory delivery and plant utilization.
  • Complex Hospital Generics (CHG) depends more directly on product availability, market access and the durability of particular hospital products.

Consumer Healthcare (PCH) has a branded distribution and advertising model. A common group multiple can obscure differences in reinvestment, working-capital intensity and earnings quality.

In Q2 FY27 CDMO revenue was INR 1,424 crore versus INR 1,044 crore a year ago. The issuer attributes improvement to utilization, execution, and demand across India and overseas sites; its materials also show 22 customer additions in H1, 110 customer audits and a Phase III pipeline increasing to 28 molecules from 25 at March 2026.

These are commercial-funnel indicators, not contracted annual revenue. Reported H1 growth of 39% in on-patent manufacturing and 51% in ADC services suggests a favorable capability mix, but absolute revenues, future wins and incremental margins for those subcategories must not be inferred without disclosed denominators.

Peter DeYoung's 28 October earnings-call response supports a nuanced network thesis. He described interest across North America, UK and India and stronger North American RFP, order-book and realized-revenue activity; he also said the hindsight preference would be fewer, larger US sites.

The footprint is both a credible option for geographically sensitive clients and a fixed-cost burden when individual plants are subscale. The Lexington sterile fill-finish project and Yapan biologics acquisition may expand differentiated capability, but neither is immediately equivalent to profitable installed capacity.

Asset return on capital and the cash cost of ramp-up are therefore critical.

CHG reported INR 849 crore versus INR 644 crore in Q2. Management cited a 48% US sevoflurane value share (IQVIA) and an initial Kenalog contribution, so it would be incorrect to label all CHG growth as organic.

PCH recorded INR 359 crore versus INR 319 crore. Its H1 Power Brands and e-commerce growth of 21% and 32% respectively are encouraging, but the disclosed shares of PCH turnover may overlap; adding them would overstate coverage.

Approximately 11% of PCH sales were invested in media and promotion, and the planned December 2026 Bayer distribution expiry introduces transition risk. Source: accepted 27 October presentation document 56662; corroborating management discussion, 28 October call document 93805.

The portfolio's central economic question is whether the CDMO profit improvement can finance compliance, plant expansion and acquisitions while the more branded and generics-driven lines continue to generate dependable cash. The issuer's segment revenue sum cannot yet be equated mechanically to consolidated sales; the financial bridge checkpoint retains the unresolved reconciliation.

3. Consolidated quarterly and half-year financial bridge

Key takeaways

  • Issuer Q2 FY27 revenue increased INR 573 crore to INR 2,617 crore from INR 2,044 crore, or 28.03% calculated YoY.
  • EBITDA rose INR 161 crore to INR 385 crore from INR 224 crore, or 71.88%, widening the calculated quarterly margin to 14.71% from 10.96% (+375 bps).
  • The operating leverage improvement is therefore observable in issuer figures; attributing it solely to utilization rather than mix and acquisitions would exceed available reconciliation.

The disclosed Q2 CDMO line was INR 1,424 crore vs INR 1,044 crore (+36.40%); complex hospital generics INR 849 crore vs INR 644 crore; and consumer health INR 359 crore vs INR 319 crore. The three segment figures sum to INR 2,632 crore, INR 15 crore above consolidated revenue. Prior-year lines total INR 2,007 crore, INR 37 crore below reported consolidated revenue. Neither difference may be assumed to be intersegment elimination without the actual segment reconciliation.

The arithmetic Q2 PBT bridge is 385 EBITDA minus 88 interest minus 233 depreciation plus 18 share of associates equals INR 82 crore; less 77 tax yields INR 5 crore PAT. H1 revenue INR 4,887 crore implies INR 2,270 crore Q1 revenue; H1 EBITDA 669 less Q2 385 implies Q1 284, while the issuer quarter table rounds/discloses Q1 as 285. Mark INR 1 crore rounding/definition discrepancy pending statutory reconciliation.

September net debt INR 4,859 crore was INR 695 crore higher than March INR 4,164 crore. Working capital rose INR 179 crore to INR 2,260 crore. Management cites acquisition and Lexington expansion effects and 3.4x net debt/EBITDA against March 3.7x. The denominator must be identified before interpreting lower leverage ratio as balance-sheet deleveraging. No cash-flow generation, share-count, enterprise value or price-based valuation should be certified until independently sourced.

Consolidated statutory cash reconciliation — material addition

The original October 27 NSE integrated Ind-AS filing reports Q2 FY27 consolidated sales of Rs 2,61,706 lakh, or Rs 2,617.06 crore, and H1 sales of Rs 4,88,698 lakh, or Rs 4,886.98 crore. This agrees with the issuer presentation's rounded Rs 2,617 crore and Rs 4,887 crore. Source amounts in lakhs must be divided by 100 to express rupee crore; a factor-of-100 error would invalidate revenue, enterprise-value and margin conclusions.

The issuer's consolidated H1 cash statement reports profit before the working-capital movements but after specified operating adjustments of Rs 671.75 crore against Rs 332.46 crore in H1 FY26. Cash generated by operations was Rs 497.43 crore, down from Rs 980.12 crore, and taxes paid were Rs 106.52 crore versus Rs 90.36 crore.

Accordingly cash from operating activities was Rs 390.91 crore, versus Rs 889.76 crore. Inventory movements absorbed Rs 267.65 crore; current other assets absorbed Rs 263.71 crore; receivables absorbed Rs 44.29 crore; offsetting trade payables supplied Rs 276.69 crore and other current liabilities Rs 155.59 crore.

These are net cash effects in the H1 statement, not direct period-end balance-sheet changes.

Cash payments for property, plant, equipment and intangibles, including CWIP and advances, were Rs 858.69 crore compared with Rs 433.22 crore a year ago. Total consolidated cash used in investing was Rs 970.47 crore compared with Rs 468.28 crore.

Financing cash outflow was Rs 131.34 crore versus Rs 360.99 crore. Operating cash of plus Rs 390.91 crore, investing cash of minus Rs 970.47 crore and financing cash of minus Rs 131.34 crore sum to a cash decrease of Rs 710.90 crore, matching the reported Rs 710.89 crore after source rounding.

This cross-check is meaningful: it does not confuse financing with operating cash or standalone subsidiary cash flow.

Management upgraded its FY27 sales growth outlook from early-to-mid-teens to approximately 19–20%, while anticipating profit growth materially above sales growth. That is a forward-looking management claim, not independently verified achievement.

On the 28 October 2026 call, management described CDMO on-patent manufacturing growth as broad-based rather than attributable to a single customer, but did not provide independently verifiable customer concentration schedules. It described approximately USD 40 million of H1 ADC services revenue across sites, while maintaining annual-only disclosure of the full ADC figures and not quantifying site utilization.

A credible buy-side model should not convert these statements into contracted revenue or disclosed utilization percentages. The Q&A directly addressed net debt: the CFO cited Lexington expansion, Kenalog acquisition, foreign-exchange movements and Yapan as contributors; management stated 3.4x net debt/EBITDA versus 3.7x in March.

This is consistent with the reported absolute net-debt increase of INR 695 crore and does not independently establish deleveraging. Monitor new business conversions, customer concentration, on-patent growth, ADC commercialization, Lexington capital efficiency and actual cash conversion.

Risks include execution delays, regulatory inspection findings, acquisition integration, financing costs, currency, and a reversal in utilization. The investor presentation cites 12 regulatory inspections and 110 customer audits during H1; this is an issuer statement, not independent verification of every site.

The distinction between 2026 H1 cash receipts and accounting EBITDA remains unresolved. Management performance should be checked against the upgraded FY27 guidance in later quarterly filings, without retroactively changing this 28 October evidence set.

Reproducible bull/base/bear stress valuation with explicit assumptions

First define a non-guidance EBITDA yardstick: H1 FY27 reported EBITDA Rs 669 crore multiplied by two equals Rs 1,338 crore. It is merely a mechanical annualized reference; seasonality, H2 strength, acquisition timing and mix mean it is not management guidance or a defensible full-year forecast.

For a sensitivity rather than a certified fair value, choose bear EBITDA 15% below Rs 1,338 crore, or Rs 1,137.3 crore; base Rs 1,338 crore; bull 15% above, or Rs 1,538.7 crore. These plus/minus 15% deviations are editorial stress assumptions, not issuer projections or probabilities.

Apply deliberately hypothetical EV/EBITDA factors of 14x bear, 18x base and 22x bull. They are NOT peer-company observed multiples, broker targets or empirically established discount rates. The implied enterprise values are Rs 15,922.2 crore, Rs 24,084.0 crore and Rs 33,851.4 crore.

Holding the September issuer-reported net debt of Rs 4,859 crore constant gives conditional equity remainders of Rs 11,063.2 crore, Rs 19,225.0 crore and Rs 28,992.4 crore. The assumptions explicitly ignore any change in acquisitions, future debt, minority ownership, lease definition and cash restrictions; independent valuation certification is therefore outstanding.

A basic share-count illustration may be calculated from the filing's approximately Rs 1,328.39 crore paid-up capital at face value Rs 10, implying about 132.839 crore nominal shares. This is not a verified fully diluted future share count.

Simple division of scenario equity by that historical basic count yields approximately Rs 83.28, Rs 144.72 and Rs 218.25 per basic share. These are mathematical illustrations, not investment price targets; they do not warrant the same confidence as company-reported profit or cash.

A genuinely investable valuation requires a dated diluted-shares bridge and separately documented minority interests, leases, excess cash and forward normalized EBITDA.

At the historical Rs 244.93 close, the nominal basic-share proxy implies market equity of roughly Rs 32,536 crore; adding September net debt gives an illustrative enterprise value around Rs 37,395 crore. Dividing by the simple Rs 1,338 crore doubled-H1 EBITDA yields roughly 28x.

Sage's existing 32.0691x EV/EBITDA cache uses a different trailing-profit denominator and a gross-debt proxy without reconciled cash; it is not a counter-proof of this normalized illustration. Avoid mixing the numerator from one date with a denominator from a different financial basis.

Reverse valuation makes the economic hurdle visible. At roughly Rs 37,395 crore market enterprise value, an illustrative 22x EBITDA factor requires Rs 1,700 crore annual EBITDA, or about 27% above the doubled-H1 yardstick.

At 18x it requires approximately Rs 2,077.5 crore, or about 55% above. Neither is issuer guidance. A one-turn increase in the EV multiple on Rs 1,338 crore EBITDA changes EV by Rs 1,338 crore; a Rs 500 crore increase in net debt, at fixed EV, lowers residual equity by Rs 500 crore.

These sensitivities are the reason capital returns, cash after investment and dilution matter even when operating momentum is convincing.

6. Catalysts, downside and falsifiable monitoring

Key takeaways

  • The strongest identifiable catalyst is sustained CDMO order conversion with improving utilization and cash returns.
  • Track requests for proposal, orders, Phase III molecules reaching commercial manufacturing, differentiated service revenue and site economics separately.
  • A customer audit or a Phase III pipeline molecule is not recognized revenue.

Verify whether stronger North American demand occurs alongside continuing Indian/UK growth rather than being offset elsewhere.

Management raised its full-year FY27 revenue-growth outlook to approximately 19-20% on the 28 October call. This is prospective guidance, not delivered growth. Observe future reported quarters relative to the Q2 consolidated revenue baseline of INR 2,617 crore and Q2 EBITDA of INR 385 crore, and distinguish actual seasonal strength from acquisitions and timing.

Persistently lower reported margin against the approximate Q2 14.7% baseline, with no explaining change in mix, would call the operating-leverage thesis into question. An improvement in both normalized margin and post-investment operating cash generation would be stronger confirmation than revenue alone.

The balance-sheet test is particularly important. Issuer material shows net debt rising to INR 4,859 crore at September 2026 from INR 4,164 crore in March. Management simultaneously cited net debt to EBITDA improving to 3.4 times from 3.7 times.

These statements need not conflict if the earnings denominator rose, but they do not establish cash deleveraging. Reconcile the trailing EBITDA basis, Lexington cash capex, Kenalog and Yapan transaction flows, currency effects, working-capital absorption and other financing before a price target or enterprise-value conclusion is published.

Principal downside mechanisms are weaker biotech funding or CDMO RFP conversion, subscale western manufacturing sites, regulatory remediation, ramp-up and integration costs, concentration or competitive pricing in CHG, PCH marketing spend without adequate incremental brand contribution, and balance-sheet stress from cash costs that outpace recurring cash generation. The December 2026 Bayer distribution transition is a dated operating watchpoint; its financial effect remains management's forward claim rather than a verified outcome.

For each upcoming quarterly filing, require consistent consolidated/segment bases, organic/acquired growth differentiation, EBIT-to-cash reconciliation, a diluted share count, and a price/market-cap/net-debt bridge. Only after those are available can the bull, base and bear valuation scenarios use defensible enterprise values or equity prices.

No fabricated probability, issuer guidance or peer multiple has been assigned here. Sources: accepted document 56662, 27 October 2026, and earnings call document 93805, 28 October 2026.

7. Dated original-source ledger and scope of certification

Key takeaways

  • S1 — Issuer-signed stock-exchange results, dated 27 October 2026, quarter ended 30 September 2026. NSE original Board outcome and statutory unaudited standalone and consolidated statements: https://nsearchives.nseindia.com/corporate/Priyankamehta_27102026210048_Outcome_of_BM_271026.pdf.
  • NSE integrated consolidated Ind-AS machine-readable filing: https://nsearchives.nseindia.com/corporate/ixbrl/INTEGRATED_FILING_INDAS_205163_27102026211803_iXBRL_WEB.html.
  • Used for exact consolidated revenue, financial basis and statutory H1 cash-flow classification.

This source was first reviewed for the specific omitted cash-flow fact; it was not used to overturn an unchanged ACCEPT decision for another document. Independent examination of all signed PDF pages and auditor limited-review detail remains outstanding.

S2 — Issuer press release/investor presentation, dated 27 October 2026, canonical accepted presentation ID 56662, available 27 October, accepted text MD5 2b2f3fe923a3b044ab4b3d934f13f509, content SHA-256 2080258cdfc2c9198ddc4107f7d8cc28d9b993f03e3936614fbef0c0fec29732. Exchange-hosted original: https://nsearchives.nseindia.com/corporate/Priyankamehta_27102026210401_PRandIRIntimation27Oct26sd.pdf.

Contains commercial activity, business mix, group debt and management guidance. The original accepted status and full-window FinBERT result are reused, not regenerated.

S3 — Original issuer Q2 call transcript, call 28 October 2026, available 30 October, canonical accepted transcript ID 93805, accepted text MD5 b828bb94c016d03d88980a53eb7edfd6, content SHA-256 81f5f19cff281f67cbd98916f515567eaaa2c975d31fd992b6b32d4c0dcd3794. Issuer URL: This supports dates, management promises, question-and-answer interpretation and debt explanation, not fabricated revenue probabilities.

Research versus certification: This is an original longform source-verified brief, not a full independently audited buy-side report. Explicit unresolved material work includes all-page original statutory PDF verification, strategic-division-to-statutory group revenue reconciliation, dilution and minority/lease claims, independently assessed peer comparables and future cash normalization.

The 14x/18x/22x illustration is an analyst assumption, not peer evidence. Source-linked facts are kept separate from model assumptions and from management assertions. No transcript or protected investor deck is reproduced wholesale.

Additional company evidence

CHART 5

Quarterly PBT

Q2 FY26₹-46 cr
Q2 FY27₹82 cr

S2

CHART 6

Q2 interest

Q2 FY26₹82 cr
Q2 FY27₹88 cr

S2

CHART 7

Q2 depreciation

Q2 FY26₹203 cr
Q2 FY27₹233 cr

S2

CHART 8

Consolidated H1 sales

H1 FY26₹3,977 cr
H1 FY27₹4,886.98 cr

S1

SOURCE REFERENCES

Original disclosures and investor presentations

  1. Original cited issuer/exchange document
  2. Original cited issuer/exchange document
  3. Original cited issuer/exchange document

Related research and comparisons

Other published Q2 FY27 reports

This is dated research, not a live market quote. Scenarios and historical performance are not guarantees.